关注
Guillermo Villacampa Javierre
Guillermo Villacampa Javierre
Vall d'Hebron Institute of Oncology and SOLTI group
在 vhio.net 的电子邮件经过验证
标题
引用次数
引用次数
年份
A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
M Castroviejo‐Bermejo, C Cruz, A Llop‐Guevara, S Gutiérrez‐Enríquez, ...
EMBO molecular medicine 10 (12), e9172, 2018
2492018
Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III …
R Dienstmann, G Villacampa, A Sveen, MJ Mason, D Niedzwiecki, ...
Annals of oncology 30 (10), 1622-1629, 2019
1922019
Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis
M Ligero, O Jordi-Ollero, K Bernatowicz, A Garcia-Ruiz, ...
European radiology 31, 1460-1470, 2021
1312021
Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
G Iacoboni, G Villacampa, N Martinez‐Cibrian, R Bailén, L Lopez Corral, ...
Cancer Medicine 10 (10), 3214-3223, 2021
1102021
Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria
I Matos, J Martin-Liberal, A García-Ruiz, C Hierro, M Ochoa de Olza, ...
Clinical Cancer Research 26 (8), 1846-1855, 2020
952020
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
SM Tolaney, P Tarantino, N Graham, N Tayob, L Parè, G Villacampa, ...
The Lancet Oncology 24 (3), 273-285, 2023
922023
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer
E Elez, J Ros, J Fernández, G Villacampa, AB Moreno-Cárdenas, ...
Nature medicine 28 (10), 2162-2170, 2022
812022
A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors
M Ligero, A Garcia-Ruiz, C Viaplana, G Villacampa, MV Raciti, J Landa, ...
Radiology 299 (1), 109-119, 2021
812021
Advanced-stage non–small cell lung cancer: advances in thoracic oncology 2018
J Remon, MJ Ahn, N Girard, M Johnson, DW Kim, G Lopes, RN Pillai, ...
Journal of Thoracic Oncology 14 (7), 1134-1155, 2019
792019
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
G Iacoboni, K Rejeski, G Villacampa, JA van Doesum, A Chiappella, ...
Blood advances 6 (12), 3606-3610, 2022
742022
Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis
A Papakonstantinou, NS Gonzalez, I Pimentel, A Suñol, E Zamora, C Ortiz, ...
Cancer treatment reviews 104, 102362, 2022
732022
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
A Oaknin, L Gladieff, J Martínez-García, G Villacampa, M Takekuma, ...
The Lancet 403 (10421), 31-43, 2024
702024
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto …
A Llop-Guevara, S Loibl, G Villacampa, V Vladimirova, A Schneeweiss, ...
Annals of Oncology 32 (12), 1590-1596, 2021
672021
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
B Pellegrino, A Herencia-Ropero, A Llop-Guevara, F Pedretti, ...
Cancer research 82 (8), 1646-1657, 2022
652022
Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes
J Montoro, L Gallur, B Merchán, A Molero, E Roldán, F Martínez-Valle, ...
Annals of hematology 97, 1349-1356, 2018
642018
MET alterations in NSCLC—current perspectives and future challenges
J Remon, LEL Hendriks, G Mountzios, R García-Campelo, SPL Saw, ...
Journal of Thoracic Oncology 18 (4), 419-435, 2023
622023
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
M Palafox, L Monserrat, M Bellet, G Villacampa, A Gonzalez-Perez, ...
Nature communications 13 (1), 5258, 2022
622022
Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy
G Iacoboni, M Simó, G Villacampa, E Catalá, C Carpio, C Díaz-Lagares, ...
Annals of hematology 100 (9), 2303-2310, 2021
582021
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
M Jiménez, E Roldán, C Fernández-Naval, G Villacampa, ...
Blood advances 6 (3), 774-784, 2022
572022
Clinical outcome and prognostic factors of patients with Richter syndrome: real‐world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)
P Abrisqueta, J Delgado, M Alcoceba, AC Oliveira, J Loscertales, ...
British journal of haematology 190 (6), 854-863, 2020
492020
系统目前无法执行此操作,请稍后再试。
文章 1–20